EGF
-
Glowing receptors help find and track cancerous growth
Under the microscope, they sparkle like emeralds, these molecules that may hold a key to understanding — and stopping — cancerous growth. Read MoreMay 18, 2017
-
New target for colorectal cancer
Vanderbilt investigators have discovered that activated epidermal growth factor receptor may be a target for therapies to prevent colorectal cancer development. Read MoreMar 17, 2017
-
New fund honors spirit of Cohen’s innovative research
When Tom Daniel, M.D., joined the Vanderbilt University faculty in December 1986, Stanley Cohen, Ph.D., had just been awarded the Nobel Prize in Physiology or Medicine for his discovery of epidermal growth factor (EGF). Read MoreAug 25, 2016
-
Probing mutant EGF receptor regulation
Understanding the regulation of mutant EGF receptors commonly found in lung cancers could lead to new targeted therapies. Read MoreOct 10, 2013
-
VU study identifies new mechanism for cancer development
Researchers at Vanderbilt University Medical Center led by a 32-year-old postdoctoral fellow have discovered a new mechanism for the development of cancer that is challenging conventional scientific wisdom. Read MoreJun 6, 2013
-
Plant compound stops colon cancer cells
Berberine, an herbal remedy for diarrhea and intestinal parasites, may be useful in colon cancer therapy. Read MoreMar 29, 2013
-
Stanley Cohen’s Nobel Prize: 25 years of progress
Twenty-five years after he received the Nobel Prize, Stanley Cohen’s discovery of epidermal growth factor continues to transform medicine. Read MoreDec 9, 2011